A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

Randomized, Double-blind, Placebo-controlled, Dose Exploration, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05987371
• Other study ID #: TQC3721-II-02
• Status: Recruiting
• Phase: Phase 2
• Start date: August 23, 2023
• Est. completion date: March 2024

Study information

• Verified date: March 2023
• Source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Contact: Weimin Li, Doctor
• Phone: +86 028-85423998
• Email: weimin003[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II clinical trial to evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 72
• Est. completion date: March 2024
• Est. primary completion date: January 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 75 Years

Eligibility

Inclusion Criteria:

• Sign an informed consent form before the study and fully understand the content, process, and potential adverse reactions of the experiment;

• Capable of using the study nebulizer correctly and complying with all study restrictions and procedures;

• Aged between 30 and 75 years old (Including critical values), both men and women;

• Body mass index(BMI) within the range of 18-30 kg/m2 (Including critical values);

• The subject has no pregnancy plan and voluntarily adopts effective contraceptive measures for at least one month from screening until the last use of the study drug;

• Diagnosed as a COPD patient according to the Global initiative for chronic obstructive lung disease (GOLD) 2023 standard, and had symptoms that met COPD for at least 1 year before screening;

• Able to conduct acceptable and repeatable lung function measurements;

• Clinical stability of COPD within 4 weeks before screening visit (V1) and between V1 visit and V2 visit;

• Long acting Bronchiectasis or short acting Bronchiectasis were not regularly used at least 14 days before screening visit (V1);

• Long acting Bronchiectasis can be stopped during the study until the end of the study, and short acting Bronchiectasis can be stopped at least 6 hours before the pulmonary function test;

• Meet the restrictions on combination medication and expect to maintain the restrictions during treatment;

• Current smoking or smoking history = 10 pack years (smoking at least 20 cigarettes per day for 10 consecutive years or smoking at least 10 cigarettes per day for 20 consecutive years, former cigarette smokers must stop smoking>6 months before visit 1).

Exclusion Criteria:

• A history of life-threatening COPD, including hospitalization in an intensive care unit and/or the need for intubation.

• Acute exacerbations of COPD requiring oral or parenteral steroid treatment within 3 months before screening (V1) or before randomization (V2).

• Received inhaled corticosteroids (ICS) treatment within 4 weeks prior to screening.

• Have a history of hospitalization for COPD at least once within 6 months prior to screening.

• Antibiotic treatment for upper and/or lower respiratory tract infection within 6 weeks before screening or before randomized visit (V2). Note: Patients with a history of upper/lower respiratory tract infection within 6 weeks cannot participate in the test, but can be re-screened 6 weeks after the infection is cured.

• COVID-19:

1. Suspected or confirmed COVID-19 infection during screening (V1), confirmed by the laboratory or based on the medical judgment of the researcher; Subjects who are known to have contact with COVID-19 positive patients. Note: Subjects should remain Asymptomatic for 14 days or more after exposure, and only after being approved by the investigator can they be re-screened.

2. Known COVID-19 infection history within 4 weeks before screening (V1);

3. Known medical history of hospitalization due to COVID-19 within 3 months before screening (V1);

4. Subjects who had COVID-19 infection before screening (V1) and had not fully recovered to participate in clinical trial operations.

• Suffering from other respiratory diseases simultaneously: a- 1. Antitrypsin deficiency, primary ciliary dyskinesia, lung cancer; Respiratory diseases such as active pulmonary infection, pulmonary tuberculosis, Bronchiectasis, Pulmonary fibrosis, pulmonary Sarcoidosis, pulmonary hypertension, etc. with significant clinical significance assessed by the researchers.

• Chest computed tomography (CT) has found clinically significant abnormalities and believes that the abnormalities are not caused by COPD, and the researchers have determined that they have an impact on the trial results or patient safety. If there is no chest CT report within 3 months before visit 1, a chest CT examination must be performed on visit 1.

• Previously underwent pneumonectomy or lung reduction surgery.

• Previously received lung rehabilitation treatment (those who have been stable for 4 weeks before screening and have remained stable during the trial period can be selected).

• Received oral steroids or roflumilast treatment for COPD within 3 months before screening (Visit 1), or received oral theophylline and/or theophylline derivatives treatment for COPD within 1 months before screening (V1).

• Use non-selective oral administration ß Receptor blockers.

• Previously received treatment with ensifentrine and HRS-9821.

• Patients receiving immunotherapy (such as Azathioprine and Cyclophosphamide) within 4 weeks before the screening period.

• The researcher evaluated that during the screening and treatment stages of this study, patients were unable to discontinue the prohibited drugs specified in the protocol.

• The patient has a history of diseases that cannot be controlled at present, including but not limited to diseases of endocrine, thyroid, nervous system, liver, gastrointestinal tract, kidney, blood, Urinary system, immunology or ophthalmic diseases which the investigator judges are clinically significant.

• History or current evidence of cardiovascular diseases with clinical significance. It is defined as any disease that the investigator believes will endanger the safety of patients when participating in the study, or any disease that may affect the effectiveness or safety analysis if the disease/condition worsens during the study; Subjects who have experienced any of the following conditions during visit 1 will be excluded:

1. myocardial infarction, unstable angina, or stroke within the past 6 months;

2. There have been unstable or life-threatening arrhythmia requiring intervention within the past 3 months;

3. New York Heart Association (NYHA) III-IV Heart Failure.

• Have unstable or uncontrollable hypertension.

• Major surgery (requiring general anesthesia) was performed within 8 weeks before the screening visit (V1), or the patient did not fully recover from the surgery during the screening visit (V1), or surgery was planned before the end of the study.

• A history of cured or uncured malignant tumors in any organ or system in the past 5 years.

• Intolerance or allergy to Salbutamol or TQC3721.

• Those who require oxygen therapy, even occasionally.

• Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study.

• Persons who have received live attenuated vaccine within 28 days before randomization, Inactivated vaccine within 7 days, or who plan to receive vaccination during the study period.

• Have a history of drug or alcohol abuse within the past 3 years.

• Individuals who have participated in any clinical trial of drugs or medical devices within 4 weeks or 5 drug half-lives (whichever is longer) prior to screening.

• The researcher believes that there are other situations that are not suitable for participation in the study.

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• TQC3721 suspension for inhalation
TQC3721 suspension for inhalation is a dual inhibitor targeting PDE3/4.
• TQC3721 matching placebo for inhalation
Placebo without active substance.
• Salbutamol sulfate inhalation aerosol
Salbutamol is short-acting ß2 receptor agonists.

Locations

Country	Name	City	State
China	The first hospital of Jilin University	Changchun	Jilin
China	Changsha Third Hospital	Changsha	Hunan
China	West China Hospital of Sichuan University	Chengdu	Sichuan
China	The First Affiliated Hospital of Guangzhou Medical University	Guangzhou	Guangdong
China	Mianyang Central Hospital	Mianyang	Sichuan
China	People's Hospital of Jiangxi province	Nanchang	Jiangxi
China	Suining Central Hospital	Suining	Sichuan
China	The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University	Wenzhou	Zhejiang
China	Wuhan Sixth Hospital	Wuhan	Hubei
China	Northern Jiangsu People's Hospital	Yangzhou	Jiangsu
China	The Affiliated Hospital of Guangdong Medical University	Zhanjiang	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The peak of Forced Expiratory Volume in the 1st second (FEV1) (4 weeks)	Change of the maximum value of FEV1 from baseline to four weeks after treatment	From baseline to four weeks after treatment.
Secondary	Morning trough FEV1	The FEV1 before administration	From baseline to four weeks after treatment.
Secondary	Average FEV1 (4 weeks)	Average FEV1 of 3 hours, 12 hours, 24 hours, 0-12 hours and 12-24 hours after administration.	From baseline to four weeks after treatment.
Secondary	Changes in FEV1	Changes in FEV1 at each time point within 24 hours after administration	From baseline to four weeks after treatment.
Secondary	COPD Assessment Test (CAT)	Change From Baseline to four weeks after treatment. The score range is 0 to 40 points (0 to 10 is minor influence; 11 to 20 are moderate; 21 to 30 are classified as severe impact; 31 to 40 is very severe).	From baseline to four weeks after treatment.
Secondary	Modified Medical Research Council (mMRC) Dyspnea Scale Score	Change From Baseline to four weeks after treatment in mMRC Scoring. The questionnaire is mainly used to evaluate the degree of respiratory distress in patients with chronic obstructive pulmonary disease. According to the symptoms of respiratory distress, the questionnaire is divided into 5 levels, with 0-1 points as less symptoms and = 2 points as more symptoms.	From baseline to four weeks after treatment.
Secondary	The peak of FEV1 (two weeks)	Change of the maximum value of FEV1 from baseline to two weeks after treatment	From baseline to two weeks after treatment.
Secondary	Trough FEV1	Change of trough FEV1 from baseline to two weeks after treatment.	From baseline to two weeks after treatment.
Secondary	Average FEV1 within 3 hours	Average FEV1 within 3 hours after administration	From baseline to two weeks after treatment
Secondary	Frequency of Rescue medication	Frequency of Rescue medication used group during the study in the experimental compared to that in the placebo group.	From baseline to four weeks after administration.
Secondary	Plasma drug peak concentration (Cmax)	Plasma drug peak concentration after administration.	Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Secondary	Time to maximum concentration (Tmax)	Time to maximum concentration (Tmax) after administration.	Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Secondary	Area Under Curve (AUC)	Area under the drug concentration-time curve.	Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Secondary	Elimination half-life (t1/2)	Apparent terminal elimination half-life after drug administration.	Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Secondary	Apparent volume of distribution (Vd)	Apparent volume of distribution after drug administration.	Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Secondary	Clearance (CL)	The total drug clearance rate of liver, kidney, etc.	Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Secondary	Plasma concentration at steady state (Cav, SS)	The plasma concentration at which the rate of administration and rate of elimination are in equilibrium.	Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Secondary	Minimum concentration (Cmin)	Plasma drug minimum concentration after administration.	Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Secondary	Degree of fluctuation (DF)	The ratio of the difference between Cmax,ss and Cmin,ss to Cav,ss.	Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Secondary	Steady state volume of distribution (Vss)	Steady state volume of distribution after administration.	Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.
Secondary	Number of cases of adverse events	Number of cases of adverse events assessed by Common Terminology Criteria for Adverse Events ( CTCAE ) v5.0.	From baseline to four weeks after treatment.
Secondary	Incidence of adverse events	Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events ( CTCAE ) v5.0.	From baseline to four weeks after treatment.
Secondary	Number of cases of serious adverse events.	Number of cases of serious adverse events assessed by Common Terminology Criteria for Adverse Events ( CTCAE ) v5.0.	From baseline to four weeks after treatment.
Secondary	Incidence of serious adverse events.	Incidence of serious adverse events assessed by Common Terminology Criteria for Adverse Events ( CTCAE ) v5.0.	From baseline to four weeks after treatment.
Secondary	Number of cases of adverse events related to study drug.	Number of cases of adverse events related to study drug assessed by CTCAE v5.0.	From baseline to four weeks after treatment.
Secondary	Incidence of adverse events related to study drug.	Incidence of adverse events related to study drug assessed by CTCAE v5.0.	From baseline to four weeks after treatment.
Secondary	The peak of FEV1 (Day 1).	Change of the maximum value of FEV1 from baseline to Day 1.	From baseline to Day 1.
Secondary	The peak of FEV1 (Day 1 to 4 weeks)	Change of the maximum value of FEV1 from Day 1 to four weeks after treatment	From Day 1 to four weeks after treatment.
Secondary	Average FEV1 (Day 2)	Average FEV1 of 3 hours, 12 hours, 24 hours, 0-12 hours and 12-24 hours after administration.	From baseline to 24 hours after first treatment.
Secondary	Average FEV1 (Day 1 to 4 weeks)	Average FEV1 of 3 hours, 12 hours, 24 hours, 0-12 hours and 12-24 hours after administration.	From Day 1 to four weeks after treatment.